Clinical trials: Neurocognitive Disorders, Mild
Alzheimer Disease, Dementia
Innovations in Dementia Empowerment and Action
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia
- Trial name
- IDEA (NCT03550131)
- Testing
- Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Washington
Mild Cognitive Impairment
Exercise Training to Improve Cognitive Function
This project is assessing the feasibility of a novel home-based exercise intervention to improve episodic memory in individuals with mild cognitive impairment.
- Trial name
- NCT03824639
- Testing
- Structured exercise, Health Education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment, Herpes Simplex 1
Valacyclovir for Mild Cognitive Impairment
Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI)…
- Conditions
- Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2
- Trial name
- VALMCI (NCT04710030)
- Testing
- Valacyclovir hydrochloride 500mg caplet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
To access the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00498602
- Testing
- ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline
- Where
- 27 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer Disease, Mild Cognitive Impairment
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
The objectives of this study are to demonstrate the feasibility of implementing a deprescribing nudge intervention using pragmatic methods, confirm that outcomes can be feasibly measured and evaluated at scale in a subsequent…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT06347172
- Testing
- Nudge Intervention
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Brigham and Women's Hospital
Healthy Participants, Mild Cognitive Impairment
Cognitive Enhancement Through Transcranial Laser Therapy
This is a mechanism-driven translational project to test the efficacy of transcranial low-level light/laser therapy (LLLT), for enhancing cognitive function in middle-aged and older adults and participants with Mild Cognitive…
- Trial name
- LLLT (NCT02851173)
- Testing
- LLLT
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Alzheimer Disease
Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease
This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.
- Trial name
- DARZAD (NCT04070378)
- Testing
- Daratumumab Injection
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marc L Gordon, MD
Mild Cognitive Disorder, Mild Cognitive Impairment
Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
The goal of this project is to determine if task-activated fMRI is sensitive to the central cholinergic deficit associated with Mild Cognitive Impairment.
- Trial name
- NCT01602198
- Testing
- Exelon [rivastigmine] transdermal patch
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic
Parkinson Disease, Cognitive Impairment, Mild
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease.
- Conditions
- Parkinson Disease, Cognitive Impairment, Mild, Speech
- Trial name
- SLAM-PD (NCT04273672)
- Testing
- Cognitive Battery, Voice, Speech and Language Analysis, Questionnaires and Clinical Assessments
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Mild Cognitive Impairment
Metformin in Amnestic Mild Cognitive Impairment
Hyperinsulinemia and type 2 diabetes (T2D) are important potential risk factors for cognitive decline and Alzheimer's disease (AD).
- Trial name
- MCI (NCT00620191)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Alzheimer Disease
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance.
- Trial name
- Elevage (NCT03980730)
- Testing
- Azeliragon
- Where
- 33 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- vTv Therapeutics
Posttraumatic Stress Disorder, Depression
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot
The goal of this pilot study is to develop and implement a larger scale, multi-site stepped collaborative care trial that targets injured patients with presentations of posttraumatic stress disorder (PTSD) and related…
- Conditions
- Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation
- Trial name
- TSOS6 (NCT02335125)
- Testing
- Motivational Interviewing, Cognitive Behavioral Therapy Elements, Psychotropic Drugs
- Volunteers
- 40 people
- Sponsor
- University of Washington
Alzheimer's Disease
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 78 weeks in the treatment of…
- Trial name
- EPOCH (NCT01739348)
- Testing
- Verubecestat (Part I and Part II), Verubecestat (Part II)
- Volunteers
- 2,211 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose.
- Trial name
- NCT00428090
- Testing
- Rosiglitazone
- Where
- 138 sites in United States, Austria and 18 more
- Volunteers
- 862 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
This 2-part, open-label study was designed to investigate the safety, tolerability, and efficacy of [18F]MK-6240, a Positron Emission Tomography (PET) imaging agent, for the quantification of neurofibrillary tangle (NFT)…
- Trial name
- NCT02562989
- Testing
- [18F]MK-6240, ~185 MBq, [18F]MK-6240, ~160 MBq
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
Evaluation of Cognitive State in Senior Subjects Using Neurosteer EEG System
This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an…
- Trial name
- NCT04683835
- Testing
- Neurosteer Aurora system
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Neurosteer Ltd.
Alzheimer Disease
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.
- Trial name
- NCT01181921
- Testing
- Galantamine
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag, S.A.
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform
Hearing Aid and Individuals With Cognitive Disorders
This is a pilot study with the aim of evaluating the feasibility of the procedures of a future clinical trial that will help determine the impacts of hearing aid interventions on older patients with Alzheimer's Disease and…
- Conditions
- Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
- Trial name
- NCT04049643
- Testing
- Audiologist-based fitting, Service-only Fitting, Device-only fitting
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Yu-Hsiang Wu
Alzheimer's Disease
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
This is a Phase II, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of Rasagiline in the regional brain metabolism on 18F-2-fluoro-2-deoxy-D-glucose…
- Trial name
- R2 (NCT02359552)
- Testing
- Rasagiline
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic